Co-cyprindiol is a medication that combines cyproterone acetate and ethinyl estradiol. It is commonly used to treat women with PCOS who have hirsutism and acne. Cyproterone acetate is an anti-androgen that reduces sebum production, leading to a reduction in acne and hirsutism. It also inhibits ovulation and induces regular withdrawal bleeds. However, it should not be used solely for contraception due to its higher risk of venous thromboembolism compared to other conventional contraceptives.

Topical retinoids are a first-line treatment for mild to moderate acne. They can be used alone or in combination with benzoyl peroxide.

Clomiphene citrate is a medication used to induce ovulation in women with PCOS who wish to conceive. It has been associated with increased rates of pregnancy.

Desogestrel is a progesterone-only pill that induces regular bleeds and provides contraception. However, its effect on improving acne and hirsutism is inferior to combination drugs like co-cyprindiol.

Isotretinoin is a medication that regulates epithelial cell growth and is used to treat severe acne resistant to other treatments. It is highly teratogenic and should only be started by an experienced dermatologist in secondary care. Adequate contraceptive cover is necessary, and patients should avoid conception for two years after completing treatment.

The progesterone-only pill requires 48 hours to become effective, except when started on or before day 5 of the menstrual cycle. During this time, additional barrier methods of contraception should be used. Since the patient is currently on day 10 of her menstrual cycle, it will take 48 hours for the POP to become effective. Therefore, having unprotected sex on day 14 of her menstrual cycle would be considered safe, and emergency contraception is not necessary.

The intrauterine device can be used as emergency contraception within 5 days of unprotected sex, but it is not necessary in this case since the POP has become effective. The intrauterine system is not a form of emergency contraception and is not recommended for this patient. Levonorgestrel is a type of emergency contraception that must be taken within 72 hours of unprotected sex.

Counselling for Women Considering the progesterone-Only Pill

Women who are considering taking the progesterone-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. When starting the POP, immediate protection is provided if it is commenced up to and including day 5 of the cycle. If it is started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a combined oral contraceptive (COC), immediate protection is provided if the POP is continued directly from the end of a pill packet.

It is important to take the POP at the same time every day, without a pill-free break, unlike the COC. If a pill is missed by less than 3 hours, it should be taken as normal. If it is missed by more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours. Diarrhoea and vomiting do not affect the POP, but assuming pills have been missed and following the above guidelines is recommended. Antibiotics have no effect on the POP, unless they alter the P450 enzyme system, such as rifampicin. Liver enzyme inducers may reduce the effectiveness of the POP.

In addition to these specific guidelines, women should also have a discussion on sexually transmitted infections (STIs) when considering the POP. It is important for women to receive comprehensive counselling on the POP to ensure they are aware of its potential effects and how to use it effectively.

Management of Vaginal Atrophy in Menopausal Women

Menopausal women often experience vaginal atrophy due to oestrogen deficiency, leading to a variety of symptoms such as dyspareunia, burning, irritation, vaginal discharge, and bleeding. It is crucial to rule out urinary and sexually transmitted infections and perform a speculum examination to exclude malignancy in the presence of vaginal bleeding. Topical therapy is the first-line management for vaginal atrophy, which can be either hormonal or non-hormonal. Hormonal treatments are more effective but have more side-effects, while non-hormonal treatments provide symptom relief to a number of patients. A combination of both therapies is also an option for maximal symptom relief. Systemic hormonal replacement therapy is offered to women who have both vaginal and systemic menopausal symptoms. Vaginal bleeding is a common side-effect of hormonal treatment and requires further investigation if it persists after the first six months of therapy.

If there is suspicion of ovarian cancer and an abdominal or pelvic mass is present, it is not necessary to perform a CA125 and US test. Instead, the patient should be immediately referred to gynaecology. Prescribing loperamide and buscopan for symptoms of irritable bowel syndrome in women over 50 years old is not appropriate as these symptoms could indicate ovarian cancer and require investigation. While waiting for the results of CA125 and ultrasound tests is usually recommended for suspected ovarian cancer patients, urgent referral to gynaecology is necessary in this case due to the presence of an abdominal mass. Although CA125 measurement should still be performed, waiting for test results to determine the need for urgent referral is not appropriate as guidelines already recommend it.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

In the NHS cervical screening programme, cervical cancer screening involves testing for high-risk HPV (hrHPV) first. If the initial test results in an inadequate sample, it should be repeated after 3 months. If the second test also returns as inadequate, then colposcopy should be performed. This is because without obtaining hr HPV status or performing cytology, the risk of cervical cancer cannot be assessed. It would be unsafe to return the patient to normal recall as this could result in a delayed diagnosis of cervical cancer. Repeating the test after 3, 6 or 12 months is also not recommended as it may lead to a missed diagnosis.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hr HPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Common Causes of Abnormal Uterine Bleeding in Women

Abnormal uterine bleeding is a common gynecological problem that can have various underlying causes. Here are some of the most common causes of abnormal uterine bleeding in women:

Endometriosis: This condition occurs when the endometrial tissue grows outside the uterus, usually in the ovaries or pelvic cavity. Symptoms include painful periods, painful intercourse, painful bowel movements, and adnexal tenderness. Endometriosis can also lead to infertility.

Ovulatory dysfunctional uterine bleeding: This condition is caused by excessive production of vasoconstrictive prostaglandins in the endometrium during a menstrual period. Symptoms include heavy and painful periods. Non-steroidal anti-inflammatory drugs are the treatment of choice.

Cervical cancer: This type of cancer is associated with human papillomavirus infection, smoking, early intercourse, multiple sexual partners, use of oral contraceptives, and immunosuppression. Symptoms include vaginal spotting, post-coital bleeding, dyspareunia, and vaginal discharge. Cervical cancer is rare before the age of 25 and is unlikely to cause dysmenorrhea, dyspareunia, dyschezia, or adnexal tenderness.

Submucosal leiomyoma: This is a benign neoplastic mass of myometrial origin that protrudes into the intrauterine cavity. Symptoms include heavy and painful periods, but acute pain is rare.

Endometrial polyps: These are masses of endometrial tissue attached to the inner surface of the uterus. They are more common around menopausal age and can cause heavy or irregular bleeding. They are usually not associated with pain or menstrual cramps and are not pre-malignant.

Understanding the Common Causes of Abnormal Uterine Bleeding in Women

Polycystic ovary syndrome (PCOS) is a prevalent disorder that is often complicated by chronic anovulation and hyperandrogenism. This condition can lead to long-term complications such as subfertility, diabetes mellitus, stroke and transient ischemic attack, coronary artery disease, obstructive sleep apnea, and endometrial cancer. These complications are more likely to occur in patients who are obese. Women with oligo/amenorrhea and pre-menopausal levels of estrogen are at an increased risk of endometrial hyperplasia and carcinoma. This risk is highest in those with menstrual cycle lengths of over three months. However, it can be reduced by inducing a withdrawal bleed every one to three months using a combined contraceptive pill or cyclical medroxyprogesterone or by inserting a mirena coil. Overweight patients can regulate their menstrual cycles and reduce the risk of endometrial hyperplasia by optimizing their BMI. Unlike in other conditions, there is no increased risk of osteoporosis in PCOS because there is no estrogen deficiency. The RCOG Greentop guidelines provide more information on the long-term consequences of polycystic ovary syndrome.

Polycystic ovary syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is believed to involve both high levels of luteinizing hormone and hyperinsulinemia, with some overlap with the metabolic syndrome. PCOS is characterized by a range of symptoms, including subfertility and infertility, menstrual disturbances such as oligomenorrhea and amenorrhea, hirsutism, acne, obesity, and acanthosis nigricans.

To diagnose PCOS, a range of investigations may be performed, including pelvic ultrasound to detect multiple cysts on the ovaries. Other useful baseline investigations include FSH, LH, prolactin, TSH, testosterone, and sex hormone-binding globulin (SHBG). While a raised LH:FSH ratio was once considered a classical feature of PCOS, it is no longer thought to be useful in diagnosis. Testosterone may be normal or mildly elevated, but if markedly raised, other causes should be considered. SHBG is typically normal to low in women with PCOS, and impaired glucose tolerance should also be checked.

To formally diagnose PCOS, other conditions must first be excluded. The Rotterdam criteria state that a diagnosis of PCOS can be made if at least two of the following three criteria are present: infrequent or no ovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound scan. Polycystic ovaries are defined as the presence of at least 12 follicles measuring 2-9 mm in diameter in one or both ovaries, and/or an increased ovarian volume of over 10 cm³.

When a woman experiences postmenopausal bleeding (PMB), the primary concern is the possibility of endometrial cancer. This is because endometrial adenocarcinoma is strongly linked to PMB and early detection is crucial for better prognosis. The patient in this scenario has two risk factors for endometrial adenocarcinoma – obesity and hypertension. Other risk factors include high levels of oestrogen, late menopause, polycystic ovarian syndrome, diabetes mellitus, and tamoxifen use.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

If a patient vomits within 3 hours of taking levonorgestrel, it is recommended to prescribe a second dose of emergency hormonal contraception to be taken as soon as possible, according to NICE guidelines. Therefore, reassuring Zoe that she is protected from pregnancy is incorrect as she needs to take another dose. Additionally, while it may be advisable for Zoe to start a regular form of contraception, this is not the most important advice to give initially. Instead, she should be offered choices of contraception, including long-acting reversible contraceptives. It is also incorrect to recommend other forms of emergency contraception, such as ulipristal acetate and the IUD, as Zoe has already taken levonorgestrel and the guidelines are clear that a second dose of this should be taken in this circumstance. However, if Zoe experiences persistent vomiting or diarrhea for more than 24 hours after taking emergency hormonal contraception, then the IUD may be offered.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Investigations for Abdominal Pain in Women of Childbearing Age

When a woman of childbearing age presents with abdominal pain, it is important to consider the possibility of gynaecological problems, including ectopic pregnancy. The first step in investigation should be to ask about the patient’s last menstrual period and sexual history, and to perform a pregnancy test measuring β-human chorionic gonadotrophin (β-hCG) levels in urine or serum.

Proctoscopy is unlikely to be beneficial in the absence of specific gastrointestinal symptoms. Ultrasonography may be useful at a later stage to assess the location and severity of an ectopic pregnancy, but transvaginal ultrasound is preferable to transcutaneous abdominal ultrasound.

Specialist gynaecological opinion should only be sought once there is a high index of suspicion for a particular diagnosis. Laparoscopy is not indicated at this point, as less invasive tests are likely to yield the diagnosis. Exploratory laparoscopy may be considered if other investigations are inconclusive.

Investigating Abdominal Pain in Women of Childbearing Age

If a woman requests it, the combined oral contraceptive pill can be prescribed 6 weeks after giving birth, even if she is breastfeeding. However, it is important to note that she can still become pregnant as early as day 21 postpartum. Therefore, if she has had unprotected sex during this time, a pregnancy test should be conducted before prescribing the pill.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Intersex and Genetic Disorders: Understanding the Different Types

Intersex conditions and genetic disorders can affect an individual’s physical and biological characteristics. Understanding the different types can help in diagnosis and treatment.

Male Pseudointersex
Male pseudointersex is a condition where an individual has a 46XY karyotype and testes but presents phenotypically as a woman. This is caused by androgen insensitivity, deficit in testosterone production, or deficit in dihydrotestosterone production. Androgen insensitivity syndrome is the most common mechanism, which obstructs the development of male genitalia and secondary sexual characteristics, resulting in a female phenotype.

True Intersex
True intersex is when an individual carries both male and female gonads.

Female Intersex
Female intersex is a term used to describe an individual who is phenotypically male but has a 46XX genotype and ovaries. This is usually due to hyperandrogenism or a deficit in estrogen synthesis, leading to excessive androgen synthesis.

Fragile X Syndrome
Fragile X syndrome is an X-linked dominant disorder that affects more men than women. It is associated with a long and narrow face, large ears, large testicles, significant intellectual disability, and developmental delay. The karyotype correlates with the phenotype and gonads.

Turner Syndrome
Turner syndrome is associated with the genotype 45XO. Patients are genotypically and phenotypically female, missing part of, or a whole, X chromosome. They have primary or secondary amenorrhea due to premature ovarian failure and failure to develop secondary sexual characteristics.

When experiencing atrophic vaginitis, the dryness of the vaginal mucosa can cause pain, itching, and dyspareunia. The first-line treatment for this condition is topical oestrogen cream, which helps to restore the vaginal mucosa. However, lubricants and moisturisers can also provide short-term relief while waiting for the topical oestrogen cream to take effect. Oestrogen secreting pessaries are an alternative to topical oestrogen cream, but using them together would result in an excessive dose of oestrogen. Sitz baths are useful for irritation and itching of the perineum, but they do not address internal vaginal symptoms. Warm or cold compresses may provide temporary relief, but they are not a long-term solution.

Atrophic vaginitis is a condition that commonly affects women who have gone through menopause. Its symptoms include vaginal dryness, pain during sexual intercourse, and occasional spotting. Upon examination, the vagina may appear dry and pale. The recommended treatment for this condition is the use of vaginal lubricants and moisturizers. If these do not provide relief, a topical estrogen cream may be prescribed.

Surgical Manoeuvre for Safe Access to the Gravid Uterus

During Gynaecological surgery, a specific manoeuvre is used to safely access the gravid uterus. The bladder is reflected downwards with the peritoneum, which also displaces the distal ureters and uterine tubes. This displacement renders these structures less vulnerable to damage during the procedure. The ovarian arteries, which are branches of the aorta, are not affected by this manoeuvre. However, the uterine artery needs to be pushed down for safe ligation as the ureters typically run superior to it. The sigmoid colon is also displaced out of the operating field using this manoeuvre, reducing the risk of injury. While the ovarian arteries are unlikely to be injured during surgery as they are more lateral, the incidence of ureteric injury is 1-2% in Gynaecological surgery, with 70% of these injuries occurring during the tying off of the uterine pedicle.

Treatment Options for Lichen Sclerosus: Topical Tacrolimus as Second-Line Therapy

Lichen sclerosus is a chronic inflammatory condition that commonly affects the genital area in men and women, presenting with pruritus and skin irritation. First-line treatment involves high-potency steroids, but if the patient fails to respond, the next step is topical calcineurin inhibitors such as tacrolimus. This immunosuppressant reduces inflammation by inhibiting the secretion of interleukin-2, which promotes T-cell proliferation. However, chronic inflammatory conditions like lichen sclerosus increase the risk of vulval carcinoma, so a tissue biopsy should be obtained if the lesion is steroid-resistant. UV phototherapy and oral retinoids are not recommended as second-line therapy due to uncertain risks, while surgical excision is reserved for severe cases. The combination of potent steroids with antibacterial or antifungal properties is a first-line option in cases of superimposed infection.

Possible Causes of Abdominal Pain and Signs of Shock in Women: Differential Diagnosis

When a woman presents with abdominal pain and signs of shock, it is important to consider several possible causes. One of the most urgent and life-threatening conditions is ectopic pregnancy, which should be suspected until proven otherwise. A positive pregnancy test and pain localized to one side, especially with evidence of shock, are key indicators. The patient should be given intravenous access, blood tests, serum β-HCG, group and save, and a transvaginal ultrasound scan if stable. If necessary, she may need to undergo a laparoscopy urgently.

Other conditions that may cause abdominal pain in women include urinary tract infection, acute appendicitis, pelvic inflammatory disease, and miscarriage. However, these conditions are less likely to present with signs of shock. Urinary tract infection would show leukocytes, nitrites, and protein on dipstick. Acute appendicitis would cause pain in the right iliac fossa, but cervical excitation and signs of shock would be rare unless the patient is severely septic. Pelvic inflammatory disease would give rise to pain in the right iliac fossa and cervical excitation, but signs of shock would not be present on examination. Miscarriage rarely presents with signs of shock, unless it is a septic miscarriage, and the cervical os would be open with a history of passing some products of conception recently.

In summary, when a woman presents with abdominal pain and signs of shock, ectopic pregnancy should be considered as the most likely cause until proven otherwise. Other conditions may also cause abdominal pain, but they are less likely to present with signs of shock. A thorough differential diagnosis and appropriate diagnostic tests are necessary to determine the underlying cause and provide timely and effective treatment.

Recommended Investigations for Abdominal Pain in Women of Childbearing Age

Abdominal pain in women of childbearing age requires careful investigation to rule out potential life-threatening conditions such as ectopic pregnancy. The following investigations are recommended:

1. Pregnancy test: All women of childbearing age presenting with abdominal pain must have a pregnancy test to rule out an ectopic pregnancy, regardless of the location of the pain.

2. Abdominal radiograph: This may be the next investigation following the pregnancy test, to rule out bowel obstruction.

3. Ultrasound: This may be indicated to assess for appendicitis, gallstone disease, or ovarian torsion, among others. However, this should take place after testing for pregnancy.

4. Exploratory laparoscopy: This would be too invasive at this stage but may take place after investigation.

5. Prophylactic antibiotics: This will be indicated if the patient requires abdominal surgery, but at present, we do not know if this patient has an abdominal, gynaecological, or urology pathology. Prophylactic antibiotics would be premature at this point.

In conclusion, a thorough investigation is necessary to determine the cause of abdominal pain in women of childbearing age. The above investigations should be conducted in a systematic manner to ensure timely and accurate diagnosis.

If a woman is not starting her contraceptive method on the first day of her period, the time until it becomes effective varies. The only option that is effective immediately is an intrauterine device (IUD), which is a T-shaped device containing copper that is inserted into the uterus. Other methods, such as the progesterone-only pill (POP), combined oral contraceptive (COC), injection, implant, and intrauterine system (IUS), require a certain amount of time before they become effective. The POP requires 2 days, while the COC, injection, implant, and IUS all require 7 days before they become effective. It’s important to consider the effectiveness and convenience of each method before choosing the best option.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progesterone hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

Hormones Involved in Pregnancy Testing

Pregnancy testing relies on the detection of specific hormones in the body. One such hormone is human chorionic gonadotropin (hCG), which is secreted by the syncytiotrophoblast of a developing embryo after implantation in the uterus. The unique subunit of hCG, β, is targeted by antibodies in blood and urine tests, allowing for early detection of pregnancy. Luteinising hormone (LH) and follicle-stimulating hormone (FSH) also play important roles in female reproductive function, but are not measured in over-the-counter pregnancy tests. Progesterone, while important in pregnancy, is not specific to it and therefore not useful in diagnosis. The hCG subunit α is shared with other hormones and is not specific to pregnancy testing.

First-Line Treatment for Couples Trying to Conceive

When a couple is trying to conceive, lifestyle measures should be the first-line treatment. This includes weight loss and quitting smoking, as both can negatively impact fertility. It’s also important to check for folic acid intake, alcohol and drug use, previous infections, and mental health issues. If the couple is having regular sexual intercourse without contraception, 84% will become pregnant within a year and 92% within two years. Therefore, further investigations and referrals to infertility services are not recommended until after a year of trying. Blood tests are not necessary if the woman is having regular periods. Sperm analysis can be performed after a year of trying, and a female pelvic ultrasound is not necessary at this point. The focus should be on lifestyle changes to improve the chances of conception.